Derek A. Wainwright, Ph.D.
@dwainwright-phd.bsky.social
Associate Professor (Tenured), Scientific Director for Brain Tumor Research, Program Leader for Cancer Biology & Therapeutics of the Cardinal Bernardin Cancer Center, at Loyola University Chicago Stritch School of Medicine
Reposted by Derek A. Wainwright, Ph.D.
Very impactful study from the Wainwright Lab at Loyola alongside the Schiltz lab at Northwestern. A new and highly potent IDO1 PROTAC! pubs.acs.org/doi/full/10....
@dwainwright-phd.bsky.social
@dwainwright-phd.bsky.social
pubs.acs.org
February 15, 2025 at 10:35 PM
Very impactful study from the Wainwright Lab at Loyola alongside the Schiltz lab at Northwestern. A new and highly potent IDO1 PROTAC! pubs.acs.org/doi/full/10....
@dwainwright-phd.bsky.social
@dwainwright-phd.bsky.social
Reposted by Derek A. Wainwright, Ph.D.
Happy to share my latest work developing IDO1 degraders. This is the result of a fantastic collaboration with @dwainwright-phd.bsky.social and his group. The medicinal chemistry was led by an amazing postdoctoral fellow Dr. Paige Monsen (now at Foghorn Therapeutics).
pubs.acs.org/doi/10.1021/...
pubs.acs.org/doi/10.1021/...
Rational Design and Optimization of a Potent IDO1 Proteolysis Targeting Chimera (PROTAC)
Indoleamine 2,3-dioxygenase 1 (IDO1) is an immunosuppressive protein that inhibits antitumor immunity through both tryptophan metabolism and nonenzymatic functions. Drugs targeting IDO1 enzyme activit...
pubs.acs.org
February 13, 2025 at 7:10 PM
Happy to share my latest work developing IDO1 degraders. This is the result of a fantastic collaboration with @dwainwright-phd.bsky.social and his group. The medicinal chemistry was led by an amazing postdoctoral fellow Dr. Paige Monsen (now at Foghorn Therapeutics).
pubs.acs.org/doi/10.1021/...
pubs.acs.org/doi/10.1021/...